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Abstract 
Asthma, allergic rhinitis (AR) and atopic dermatitis are very common in young people, but in the latest decades it was 
increasingly recognized that also individuals of higher ages, including the population over 65 years, are concerned. 
Actually, it is now acknowledged the aging does not considerably alter the immune response to allergens. Allergen 
immunotherapy (AIT) is the only treatment that works on the causes of allergy, but elderly people are commonly 
excluded from AIT, except the cases of insect sting allergy. A number of recent studies showed that aged individu-
als also successfully respond to AIT for respiratory allergy. Therefore, there is no reason to exclude elder patients from 
AIT. Anyhow, clinical conditions that are considered absolute or relative contraindications are quite frequent in this 
aged population, thus the risk/benefit ratio must be carefully evaluated for each patient, taking into account that 
the more frequent occurrence of co-morbidities and the consequent need of daily-based multidrug regimen can 
favor adverse effects. An important issue concern the ability of AIT, and particularly of sublingual immunotherapy, to 
significantly improve the quality of life, that often is particularly impaired in the elderly, reducing symptoms and drugs 
consumption.
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Background
Asthma, allergic rhinitis (AR) and other atopic diseases 
(e.g. food allergy or atopic dermatitis) are very common 
in young people, but it is now recognized they can also 
affect individuals of higher ages. For instance, AR was 
reported to affect up to 5–10% of the population over 
65 years [1]. However, a global decline of the prevalence 
of allergic disorders in elderly, at least on epidemiological 
basis has been repeatedly claimed. This might be ascribed 
to the expected decrease in serum IgE antibodies due to 
an unbalance of cytokines and soluble factors involved in 
its production. However, in studying non-allergic individ-
uals aged 20–93  years, assessing serum IgE, sCD23 and 
Th2 type cytokine production, IgE levels were not signifi-
cantly different between young and old subjects [2]. This 
was confirmed in another similar study [3]. These results 
suggest that the type 2 cytokine pattern is not necessarily 
defective in older age. Data also confirmed that IL-13, a 
key cytokine in IgE regulation, is not impaired in old sub-
jects. Although IL-4 has been considered the most criti-
cal cytokine linked to allergic responses and immunity 
against parasites, recent observations indicate that IL-13 
has equal or even greater importance in those processes. 
IL-4 and IL-13 share several functional properties, how-
ever IL-13 can independently induce class switching 
and IgE secretion from human B cells. In addition, IL-13 
enhances expression of CD23 and of the major histo-
compatibility complex class II antigens, and may act as 
a monocyte chemoattractant [4, 5]. The clinical find-
ings indicating that the allergic reactivity could decrease 
with age [6, 7] make ageing an interesting in vivo model 
to study the waning of allergic response. Yet, there is not 
sufficient information to establish that the frequency 
of onset of allergic symptoms, as well as their severity, 
declines with aging. According to the aforementioned 
aspects, the clinical use of allergen specific immunother-
apy (AIT) has been so far considered of little interest in 
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the elderly, since AIT is commonly used in young peo-
ple, with a well-defined TH2-high immunological pheno-
type. We review herein the main immunologic aspects of 
aging, according to the presence of allergic diseases, and 
the current evidence on the use of AIT in elderly patients.
Aging and the immune system
Immunosenescence is a complex process in which 
genetic and environmental factors are involved, charac-
terized by a “remodeling” more than a “decline” of the 
immune system, and associated to various factors: oxi-
dative stress, apoptotic phenomena, increased produc-
tion of pro-inflammatory lymphokines [8]. This results 
in a state of chronic, low-grade, inflammation described 
by some authors as “inflamm-aging” [9]. The cells of the 
immune system are constantly renewed by the hemat-
opoietic stem cells, but during senescence this activity 
declines and the overall amount of hematopoietic tissue 
decreases. This event also seems related to the shorten-
ing of telomeres [10]. Thymic involution process in the 
elderly goes along with the reduction of naϊve T cells, 
although the total number of T cells does not undergo 
large displacements due to the increase in population of 
non-regulatory cells CD8+ CD45RO+ CD25+, that rep-
resent a promising biomarker of immune competence 
in old age. In the elderly a reduced response of T cells to 
growth factors and specific antigens can be documented 
[11]. The compartment of B cells is also affected by age-
ing and this influences the efficiency of cooperation 
between T and B lymphocytes. Even if the total B cells 
does not change, the number of memory B lymphocytes, 
becoming less sensitive to apoptosis, increases. At the 
same time, the naϊve B cells are reduced [12]. All these 
changes may result in an enhancement of monoclonal 
serum immunoglobulins. The role of regulatory T cells 
(Treg), a cell subsets with regulatory function, includ-
ing CD4+ and CD8+ Treg, deserves special attention 
in the elderly. CD4+ Tregs are involved in suppressing 
the activation, proliferation, and cytokine production, 
as well as the function of dendritic cells. The Tregs are 
characterized by the expression of IL-2R α-chain (CD25) 
and CTLA-4. The transcription factor FoxP3 (Forkhead 
box P3) plays an important role in the function of Tregs. 
The naturally occurring CD4+ and CD8+ Treg increase 
in the elderly and have equivalent expression of CTLA-4 
and equivalent regulatory function with cytokine pro-
duction after polyclonal T cell stimulation compared to 
younger subjects, while the number of inducible CD4+ 
and CD8+ Treg decreases with advancing years [13]. 
The relevance of these cells in the elderly is not yet fully 
clarified in relation to immunosenescence. In particular, 
the Tregs induce down-regulation of mast cells, baso-
phils and eosinophils through the production of IL-10 
and TGF-β and may also induce reduction of Th2 cells 
and their cytokines. In turn, IL-10 and TGF-β elicit the 
suppression of IgE by B lymphocytes and, in particular, 
IL-10 causes the switch towards IgG4 producing plasma 
cells and consequently to an increased synthesis of aller-
gen-specific IgG4 isotype blocking antibodies [14, 15]. 
Recently, it was identified in the senescence an immuno-
logical risk phenotype (IRP) characterized by inversion of 
the CD4/CD8 ratio, increase in CD8 + CD28 − lympho-
cyte population, identified as memory/effector cells and 
reduction of B lymphocytes. In addition, patients with 
IRP manifested a marked serum positivity for cytomeg-
alovirus and the increase of proinflammatory cytokines, 
including in particular IL-6, IL-1β, tumor necrosis fac-
tor (TNF)-α and acute phase proteins [16]. An interest-
ing research in elderly patients has shown not only an 
enhancement of the type 1 cytokines such as IL-1, inter-
feron (IFN)-γ and TNF-α, whose role is of great impor-
tance for the increase of cancer and chronic infections, 
but also of type 2 such as IL-4, IL-5, IL-10, which con-
stitutes the substrate for the development of allergic dis-
eases [2]. In particular, in cytokine cultures stimulated 
with PHA, the production of T-helper 2 cytokines does 
not appear to be significant different in young and elderly 
subjects. As it is well known that in allergic patients there 
is an overproduction of Th2 cytokines, that can induce 
the isotopic switch of B cells toward IgE isotype immu-
noglobulins and recall on-site cells responsible for the 
allergic inflammation (mast cells and eosinophils), the 
authors concluded that there is no valid justification for 
the statement that allergic diseases decline in the elderly. 
Moreover, the same authors showed that IL-13, that plays 
a key role in the regulation of IgE, is not affected in the 
elderly [2] thus confirming that the occurrence of aller-
gic reactions in the elderly is supported by high serum 
levels of IgE and type 2 cytokines. However, data on the 
production of IgE in the literature are contradictory. In 
fact, in opposition to the claim that the levels are reduced 
in the elderly [17], in the most recent literature there is 
increasing evidence that in the allergic disease IgE levels 
are perfectly comparable to those found in young sub-
jects [2, 18]. We must remember that an efficient IgE 
response requires both the presence of IL-4 or IL-13 and 
also a physical interaction between T and B-cells, involv-
ing a number of surface and adhesion molecules [19, 20], 
that include the CD40/CD40L interaction that is defec-
tive in old subjects [21]. However, these studies analyzed 
young and old non-allergic individuals, while it would be 
of greater interest to compare these parameters in aller-
gic young and old subjects.
Alterations of innate immunity have an essential role 
and the studies on the issue have identified a separate 
trend in the field of immunogerontology, beginning 
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with the reduction of epithelial barriers in the skin and 
mucous membranes, both at respiratory and gastroin-
testinal tract [22]. As regards the immunoglobulins of 
IgA type at the mucosal level, significant changes can 
be found with a marked increase of monomeric IgA1, 
both in serum and in saliva. Some changes, especially 
in the functional aspects related to chemotaxis, phago-
cytosis and oxidative burst are shown both in the com-
partment of neutrophils and macrophages. In addition, 
it is possible to observe reductions in the level of mac-
rophage-derived chemokines, including macrophage 
inflammatory protein (MIP)-1α, MIP-1β and eotaxin. 
The natural killer (NK) cells do not decrease in number, 
indeed their absolute number was found to increase in 
geriatric patients. However, the reduced production of 
IL-2, of critical importance in the processes of lympho-
cyte activation and killing, induces a deficiency of cyto-
toxic function in which the numerical increase may occur 
for a mere compensatory mechanism [23]. Also, den-
dritic cells play an important role, both in the innate and 
adaptive immunity. These cells have the role to start the 
immune response with the function of antigen present-
ing cells (APC), becoming able to process the antigen and 
to secrete cytokines. The prolonged administration of 
allergen as occurs during AIT promotes the production 
of high levels of IL-12 and IL-27, favouring allergen-spe-
cific switches from the Th2 to the Th1 and Th17 pheno-
type and the expression of NK and NKT cells which in 
turn induce the increased levels of IFN-γ and activation 
of APC [24]. The role of vitamins and trace elements, 
including iron and zinc should be also considered, espe-
cially in the light of the frequent conditions of malnutri-
tion in geriatric patients. Vitamin D, and especially its 
active form, is very important in both innate and adap-
tive immunity. In particular calcitriol is able to act on 
APCs and on T lymphocytes by determining inhibition of 
inflammatory responses through induction of T reg [25].
Allergen sensitizations and AIT in the elderly
Elderly spend most of their time indoors and conse-
quently the most frequent allergen sensitizations are 
towards indoor allergens, such as house dust mites, cock-
roaches, furred pets [26]. AIT is an important guideline-
approved therapy for AR and asthma, which can modify 
the disease’s natural history, with a long lasting effect 
on symptoms after its cessation [27]. Indeed, IgE posi-
tivities reveal sensitization, but clinical allergy has to be 
confirmed on the ground of evidence of a relationship 
between results of IgE test and occurrence of symptoms 
from exposure to the specific allergen, as well as by dem-
onstration of concomitant inflammation in the airways as 
assessed by the presence of eosinophils in nasal smears 
and increase of FeNO [28]. These investigations can be 
easily performed and are mandatory for the AIT indica-
tion in these conditions. A large number of studies con-
firmed the efficacy and safety of AIT in AR and asthma 
[29], which is especially related to the mechanism of 
action itself [15]. Of note, only few studies were designed 
for AIT in the elderly. Therefore, specific indications and 
contraindications for AIT in old people are not yet avail-
able. Currently, allergists can rely, their everyday practice 
only on the general guidelines also for the elderly.
The  GA2LEN/EAACI pocket guide on AIT for AR and 
asthma points out that there is not an upper age limit 
for prescribing AIT [28], as also suggested by the recent 
EAACI (European Academy of Allergy and Clinical 
Immunology) position paper on the clinical contraindica-
tions to AIT [30], that gave no indication on the upper 
age limit. In the mentioned document, the only absolute 
contraindications to AIT were the presence of uncon-
trolled asthma, autoimmune disorders not responding to 
therapy, active immune-deficiency and active malignan-
cies. These chronic diseases are frequent among elderly 
and it is, therefore, warranted to collect a detailed medi-
cal history before prescribing AIT. Uncontrolled asthma 
can depend on an inappropriate therapy and/or poor 
compliance by the patient. If adequate adjustment of 
therapy and careful education of the patient allows a good 
control of asthma symptoms, AIT can be administered.
Autoimmune diseases in remission phase are consid-
ered a relative contraindication. Concerning hymenop-
tera venom immunotherapy (VIT), the position paper 
states “VIT is a highly advised option in high-risk venom 
allergic patients” [30]. There are few data on the risk of 
developing autoimmune diseases. Only a Danish obser-
vational study on 18,841 patients treated with subcutane-
ous immunotherapy (SCIT) vs. 428,484 controls treated 
with drug therapy for over 10 years found that there was 
a lower incidence of autoimmune diseases in patients 
undergoing subcutaneous immunotherapy (SCIT) [31]. 
In a recent survey among American allergists, it was 
observed that AIT (VIT and pollen SCIT) performed in 
patients with stable autoimmune diseases had an high 
safety profile [32, 33]. Concerning cancer, there is cur-
rently no evidence of a new onset or relapse when admin-
istering AIT. The possibility that the immunomodulation 
stimulated with AIT may have a negative effect on the 
natural history of cancer is the real concern about pre-
scribing AIT [34]. A study from Austria study analyzed 
the use of AIT in six patients with cancer [35]. One of 
them received SCIT after 14 years of melanoma diagnosis 
without presenting relapse of the malignancy during AIT 
for house dust mites, while another patient interrupted 
SCIT for grass-pollen because the diagnosis was made 
few months after AIT initiation. Another patient under-
going VIT had a relapse of breast cancer 3 months after 
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having reached the maintenance dose of immunotherapy, 
but she ended the 5 years course of VIT while maintain-
ing the neoplastic disease under control. No immuno-
logic mechanisms able to account for a negative effect of 
AIT on cancer were detected thus far.
Cardiovascular diseases, such as unstable angina, 
recent myocardial infarction, significant arrhythmia, and 
uncontrolled systemic hypertension, are very common 
in old people. The EAACI document considers them as 
a relative contraindication for inhalant AIT and advises 
to accurately evaluate the current status of the disease 
before starting AIT [30]. In fact, the Danish observational 
study cited above pointed out that SCIT was associated 
with a lower incidence of acute myocardial infarction 
and a lower risk of developing ischemic heart disease, 
compared to medical conventional therapy [31]. Also 
the presence of chronic pulmonary diseases (not only 
asthma) that reduce lung function must be evaluated in 
elderly patients before administering AIT [36].
A daily-based multidrug regimen is widely diffuse in 
population over 60 years and antihypertensive drugs are 
among the medications most frequently taken. In every-
day practice the allergist often encounters patients who 
take β-blockers and ACE-inhibitors. In a study on murine 
models, Nassiri et  al. stated that the use of β-blockers 
slightly aggravates an anaphylactic reaction, while the 
combined therapy with β-blockers and ACE-inhibitors 
synergistically could worsen anaphylaxis, due to their 
action on reducing the mast-cell activation threshold 
[37]. Clinically, β-blockers use is considered a relative 
contraindication for VIT, because the block of β1 and 
β2-receptors decreases the epinephrine action in case 
of anaphylaxis. However, β-blockers may be replaced by 
other kind of drugs in case of hypertension but not in 
case of arrhythmia or ischemic disease. Also ACE-inhib-
itors use is controversial in patients undergoing VIT, but 
do not represent a contraindication for inhalant AIT 
[30]. Importantly, the possible contraindications to use 
β-blockers and ACE-inhibitors concern only SCIT and 
not sublingual immunotherapy (SLIT).
Other chronic diseases are common in the elderly and 
must be evaluated before prescribing AIT. Patients with 
psychiatric or mental disorders could be not enough 
compliant or can be unable to report early symptoms 
of AIT side-effects. Concerning drug treatment of such 
disorders, the use of monoamine oxidase inhibitors is 
not a contraindication for AIT, but it must be considered 
that their action combined with epinephrine could cause 
severe hypertension and tachycardia [38].
On the other hand, AIT has an important outcome in 
reducing the risk of side effects to anti-allergic drugs, 
such as oral corticosteroids (diabetes, osteoporosis, 
hypertension, etc.), and anti-histamines (sedation, anti-
cholinergic effects).
According to the available data there are not real limi-
tations in administering AIT to elderly people if we con-
sider only age as a limit, but thus far studies on AIT in 
the elderly are rare, because they are often excluded 
(mainly for concomitant diseases requiring daily drug-
regimen) or present in a small number. Another limit 
concern defining the elderly age: in developed countries 
people over 65 of age is usually considered as elderly 
[39], but often the inclusion age criteria to participate 
to an AIT trial is 60  years or less. The first study about 
efficacy and safety of AIT in old patients was performed 
in 1993 by Armentia et  al. [40] on 22 geriatric patients 
treated with AIT, in whom a significant clinical improve-
ment and a decrease in drug use was achieved. In 2000 
Eidelman et al. demonstrated for the first time that AIT 
was effective in elderly as much as in the younger, treat-
ing with SCIT otherwise healthy patients over 60  years 
of age. In this case the authors chose, as control group, 
patients with similar allergic history before AIT, but 
aged ≤  60  years, obtaining a similar good response in 
both groups of patients [41]. In 2004 Asero investigated 
whether SCIT could be safely performed in elderly sen-
sitized to seasonal allergens (birch and ragweed); 39 
subjects (aged between 55 and 70 years) with a disease’s 
duration of less than 10  years were included. Patients 
underwent AIT for 1–5  years, achieving a lower use of 
cetirizine (p < 0.001) and/or salbutamol (p < 0.05), com-
pared to controls [42].
In recent years an increasing number of studies 
addressed the safety and efficacy of SLIT [43]. The first 
study investigating SLIT in elderly population was con-
ducted in 2008 by Marogna et  al. In the overall study 
population of 167 patients (including subjects aged 
18–65 years) with AR and mild asthma due to dust mite 
allergy, 40 patients were aged more than 55  years [44]. 
The patients underwent SLIT with a dust mite extract 
and the results were compared to a control group treated 
with standard drug treatment. The end points were symp-
toms and drug scores every month, respiratory function 
tests, metacholine challenge and eosinophils counts at 
the start and at the end of the study. The authors found in 
the SLIT group an improvement in all examined variables 
(p < 0.001), achieving also a lower number of new aller-
gen sensitizations (p  =  0.03), compared to the control 
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group. The results were similar in both young and elderly 
patients as long as the disease had started fairly recently. 
However, it is needed to underline that no elderly subject 
was included, according to the common accepted limit 
age stated above [39]. The same limit is present in the 
trial by Baptistella et al. who treated 104 patients with AR 
over 55 of age (55–74 years) with SLIT for dust mites for 
1  year, but there was no information on the number of 
patients aged more than 65 years [45]. Moreover, patients 
undergoing any kind of treatment for any comorbid-
ity were excluded. The authors demonstrated the effi-
cacy and the safety of SLT in their patients, with clinical 
improvement on rhinitis symptoms and absence of side 
effects. The critical issue regarding these SLIT studies is 
that they were not blinded.
The first two double-blind placebo-controlled trials 
were performed recently on a population over 60 years of 
age. In the initial trial, Bozek et al. recruited 106 patients 
between 60 and 75  years of age with demonstrated AR 
due to dust mites [46]; 51 subjects underwent SLIT and 
the other 57 were included in the placebo group. After 
3  years of treatment the patients treated with SLIT had 
a significant improvement of 44% (p  <  0.05) in symp-
toms and of 35% for the medication scores (p < 0.05). No 
side effect was reported. The same authors examined the 
safety and the efficacy of SLIT for grass pollen allergy in 
a population aged over 60 years [47]; 78 subjects between 
60 and 70  years of age were included in the trial and 
divided in two groups: 41 patients were treated with 
SLIT and 37 were in the placebo group. At the end of 
AIT (3 years), the total nasal symptom score and the total 
medication score in the SLIT group improved signifi-
cantly, obtaining a decrease of 64 and 51%, respectively 
(p  <  0.05 for both). Only three patients had common 
local side effects, such as oral itching and facial flushing, 
while no systemic reaction was observed. Recently, these 
authors also investigated the safety and efficacy of pre-
seasonal SCIT for grass pollen allergy in 62 patients older 
than 65  years with seasonal AR. It was demonstrated 
that the total nasal symptom score decreased by 76% 
and that the total medication score of the active group 
decreased by a maximum of 62% in the active group after 
3 years of AIT. Moreover, no adverse systemic reactions 
were reported during therapy [48]. Studies about AIT in 
elderly are summarized in Table 1.
Conclusions
The older age per se does not preclude the prescription 
of AIT, that should be considered in elderly individuals 
when there is a clear indication. Anyhow, clinical condi-
tions that are considered absolute or relative contrain-
dications are quite frequent in this age population and 
can interfere with AIT effectiveness and safety. The risk/
benefit ratio must be carefully evaluated for each patient, 
taking into account that in the elderly the frequent occur-
rence of co-morbidities and the consequent need of 
daily-based multidrug regimen can favor adverse effects 
as well as drug interactions [49]. An important issue con-
cern the ability of AIT, particularly SLIT, to significantly 
improve the quality of life, reducing symptoms and drugs 
consumption [43]. Actually, a study stated that in patients 
with AR the impairment of quality of life is significantly 
higher in elderly than in young people [50]. In older 
patients, this may result in altered cognitive functions 
giving rise to a vicious circle with unremitting worsen-
ing, that warrants to be broken by treatment with signifi-
cant effectiveness and particularly with persistence over 
time also following its stopping, thus ensuring to patients 
Table 1 AIT studies in elderly
AR allergic rhinitis, AA allergic asthma, SCIT subcutaneous immunotherapy, SLIT sublingual immunotherapy, HDM house dust mites, N.A. not available data
Study N. patients AR/AA Allergen SCIT/SLIT Length (years)
Armentia et al. [40] 22 NA NA SCIT 1
Eidelman et al. [41] 26 AR and AA NA SCIT NA
Asero [42] 39 AR and AA Birch and ragweed SCIT 1–5
Marogna et al. [44] 40 AR and AA HDM SLIT NA
Baptistella et al. [45] 104 AR and AA HDM SLIT 1
Bozek et al. [46] 106 AR HDM SLIT 3
Bozek et al. [47] 78 AR Grass pollen SLIT 3
Bozek et al. [48] 62 AR Grass pollen SLIT 3
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a good control of allergic symptoms with no or minimal 
use of symptomatic drugs. Such requirement is fulfilled 
by the therapeutic performances of AIT.
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